Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.57 |
| ▸ | DRD3 | P35462 | 3/20 | 0.57 |
| ▸ | HTR1A | P08908 | 9/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16233581 | 0.87 | CHRM2 (0.64) | DRD2DRD3CHRM2CHRM1CHRM3 | |
| SCHEMBL17637593 | 0.83 | DRD2 (0.71) | DRD2DRD3CHRM2CHRM1CHRM3 | |
| SCHEMBL8351546 | 0.83 | DRD2 (0.71) | DRD2DRD3CHRM2CHRM1CHRM3 | |
| SCHEMBL385443 | 0.81 | DRD2 (0.73) | DRD2DRD3HTR1ACHRM2CHRM1 | |
| SCHEMBL16482975 | 0.81 | DRD2 (0.54) | DRD2DRD3HTR1ACHRM2CHRM1 | |
| SCHEMBL24029258 | 0.81 | DRD2 (0.54) | DRD2DRD3HTR1ACHRM2CHRM1 | |
| SCHEMBL14545524 | 0.81 | DRD2 (0.54) | DRD2DRD3HTR1ACHRM2CHRM1 | |
| SCHEMBL31324598 | 0.81 | DRD2 (0.73) | DRD2DRD3HTR1ACHRM2CHRM1 | |
| SCHEMBL8856952 | 0.79 | DRD2 (0.53) | DRD2DRD3HTR1ACHRM2CHRM1 | |
| SCHEMBL9568706 | 0.79 | HTR1A (0.63) | DRD2DRD3HTR1ACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9416139-B2 | Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-08-16 | — | — | US | disclosed |
| US-20160219879-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-08-04 | — | — | US | disclosed |
| US-9326513-B2 | Fungicidal compositions | SYNGENTA PARTICIPATIONS AG (CH) | 2016-05-03 | — | — | US | disclosed |
| US-9303061-B2 | Spiro compounds as Hepatitis C virus inhibitors | Sunshine Luke Pharma Co., Ltd. (CN) | 2016-04-05 | — | — | US | disclosed |
| US-20140335201-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-11-13 | — | — | US | disclosed |
| US-20140147412-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-05-29 | — | — | US | disclosed |
| EP-2268625-B1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF | Bayer Pharma AG (DE) | 2012-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335201-A1 | FUNGICIDAL COMPOSITIONS | CYP1B1, CYP4B1, DDT | DRD2 2150/4885DRD3 2305/4885HTR1A 3652/4885 |
| US-20140147412-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | HAVCR2, SORD, SLC10A1 | DRD2 3745/4885DRD3 2628/4885HTR1A 2833/4885 |
| US-20160219879-A1 | FUNGICIDAL COMPOSITIONS | CYP1B1, CYP4B1, DDT | DRD2 2150/4885DRD3 2305/4885HTR1A 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.